Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients

Neurology

Volumn 80, Issue 18, 2013, Pages 1698-1701

  Bartus, Raymond T ^a   Baumann, Tiffany L ^a   Siffert, Joao ^a,g   Herzog, Christopher D ^a   Alterman, Ron ^b,h   Boulis, Nicholas ^c   Turner, Dennis A ^d   Stacy, Mark ^d   Lang, Anthony E ^e,f   Lozano, Andres M ^e   Warren Olanow, C ^b  

^a Ceregene Inc   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f TORONTO WESTERN HOSPITAL   (Canada)

^g AVANIR PHARMACEUTICALS   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEURTURIN; PARVOVIRUS VECTOR;

ADULT; ARTICLE; BRAIN SURGERY; CLINICAL ARTICLE; DREAMING; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSKINESIA; FEASIBILITY STUDY; FEMALE; GENE VECTOR; HEADACHE; HUMAN; INCISION SITE PAIN; LOW DRUG DOSE; MALE; MESENCEPHALON; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RISK ASSESSMENT; SIDE EFFECT; STEREOTAXIC SURGERY; SUBSTANTIA NIGRA; TREATMENT PLANNING; VIRAL GENE THERAPY;

DEPENDOVIRUS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; MALE; MICROINJECTIONS; MIDDLE AGED; NEURTURIN; PARKINSON DISEASE; STEREOTAXIC TECHNIQUES; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 84879086501     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182904faa     Document Type: Article

References (13)

1. Bartus RT, Baumann T, Brown L, Kruegel B, Ostrove JM, Herzog CD. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating 'clinical proof-of-concept' for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiol Aging 2013;34:35-61.
2. Marks WJ, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:1164-1172.
3. Bartus RT, Herzog CD, Chu Y, et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 2011;26:27-36.
4. Lu L, Wang X, Wu P, et al. Role of ventral tegmental area glial cell line-derived neurotrophic factor in incubation of cocaine craving. Biol Psychiatry 2009;66:137-145.
5. Su X, Kells AP, Huang EJ, et al. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 2009;20:1627-1640.
6. Manfredsson FP, Tumer N, Erdos B, et al. Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 2009;17:980-991.
7. Deuschl G, Herzog J, Kleiner-Fisman G, et al. Deep brain stimulation: postoperative issues. Mov Disord 2006;21(suppl 14):219-237.
8. Mendez I, Dagher A, Hong M, et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study: report of three cases. J Neurosurg 2002;96:589-596.
9. Bartus RT, Brown L, Wilson A, et al. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis 2011;44:38-52.
10. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7:400-408.
11. Manfredsson FP, Burger C, Rising AC, et al. Tight Longterm dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther 2009;17:1857-1867.
12. Baumann T, Lang AE, Lozano AM, Olanow CW, Bartus RT. AAV2-neurturin (CERE-120) and Parkinson's disease: the safety and feasibility of combined substantia nigral and putaminal stereotactic targeting via a Phase 1/2b clinical trial in advanced Parkinson's disease. Presented at the 16th International Congress of Parkinson's Disease and Movement Disorders; June 20, 2012; Dublin.
13. Bartus RT. Translating the therapeutic potential of neurotrophic factors to clinical 'proof of concept': a personal saga achieving a career-long quest. Neurobiol Dis 2012;48:153-178.